SAN FRANCISCO (MedPage Today) -- The addition of cetuximab (Erbitux) to definitive chemoradiation failed to improve survival in an unselected population with esophageal cancer, a randomized trial showed. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment